← Drug database

Pemetrexed Baxter (pemetrexed)

Generic
Region
🇪🇺 EU
Active substance
pemetrexed
Company
Baxter Holding B.V.
Status
Withdrawn
Therapeutic area
Carcinoma, Non-Small-Cell Lung; Mesothelioma
CHMP opinion
Thu 13 Oct 2022
EU approval
Fri 09 Dec 2022
Designations
Generic
Application
EMEA/H/C/005848
ATC
L01BA04
Official record
www.ema.europa.eu

Indication

Malignant pleural mesotheliomaPemetrexed Baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. Non-small cell lung cancerPemetrexed Baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1). Pemetrexed Baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5.1). Pemetrexed Baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Pemetrexed Baxter

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.